[1]陈兴慧谢睿刘瑶张靖琨李璞冀花.健脾消萎汤联合胶体果胶铋胶囊治疗对慢性萎缩性胃炎患者胃泌素17、胃蛋白酶原、炎性因子水平的影响[J].现代中医药,2024,(01):074-78.[doi:10.13424/j.cnki.mtcm.2024.01.016]
 CHEN XinghuiXIE RuiLIU YaoZHANG JingkunLI PuJI Hua.Therapeutic Effect of Jianpi Xiaowei Decoction Combined with Colloidal Pectin Bismuth Capsules on Chronic Atrophic Gastritis and Its Effects on Levels of Gastrin 17,Pepsinogen,and Inflammatory Factors[J].Modern Traditional Chinese Medicine,2024,(01):074-78.[doi:10.13424/j.cnki.mtcm.2024.01.016]
点击复制

健脾消萎汤联合胶体果胶铋胶囊治疗对慢性萎缩性胃炎患者胃泌素17、胃蛋白酶原、炎性因子水平的影响()
分享到:

《现代中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2024年01期
页码:
074-78
栏目:
出版日期:
2024-01-20

文章信息/Info

Title:
Therapeutic Effect of Jianpi Xiaowei Decoction Combined with Colloidal Pectin Bismuth Capsules on Chronic Atrophic Gastritis and Its Effects on Levels of Gastrin 17,Pepsinogen,and Inflammatory Factors
文章编号:
1672-0571(2024)01-0074-05
作者:
陈兴慧1谢睿1刘瑶1张靖琨1李璞1冀花2
1.汉中市中医医院 脾胃病科,陕西 汉中 723100;
2.商洛市中心医院 中西医结合科,陕西 商洛 726000
Author(s):
CHEN Xinghui1XIE Rui1LIU Yao1ZHANG Jingkun1LI Pu1JI Hua2
1.Spleen and Stomach Disease Department of Hanzhong Traditional Chinese Medicine Hospital,Shaanxi Hanzhong 723100,China;
2.Integrated Traditional Chinese and Western Medicine Department of Shangluo Central Hospital,Shaanxi Shangluo 726000,China
关键词:
关键词:慢性萎缩性胃炎健脾消萎汤胶体果胶秘胶囊胃泌素-17胃蛋白酶原
Keywords:
Key words:Chronic atrophic gastritisJianpi Xiaowei decoctionColloidal pectin secret capsulesGastrin-17Pepsinogen
分类号:
R256.3
DOI:
10.13424/j.cnki.mtcm.2024.01.016
文献标志码:
A
摘要:
摘要:目的 观察健脾消萎汤联合胶体果胶铋胶囊治疗慢性萎缩性胃炎对患者胃泌素-17(gastrin 17,G-17)、胃蛋白酶原(pepsinogen,PG)、炎性因子水平的影响。方法 选取2019年6月—2022年6月前来我院治疗的慢性萎缩性胃炎患者80例,随机分为对照组(40例,胶体果胶铋胶囊)、治疗组(40例,胶体果胶铋胶囊+健脾消萎汤),均给予基础治疗,评估疗效,测量血清炎性因子及PG、GAS-17水平。结果 治疗组总有效率显著高于对照组(P<0.05);治疗后治疗组血清白介素(interleukin,IL)-2、IL-6水平显著低于对照组(P<0.05);治疗后治疗组血清PGⅠ、G-17水平显著高于对照组,PGⅡ水平显著低于对照组(P<0.05)。结论 健脾消萎汤联合胶体果胶秘胶囊治疗慢性萎缩性胃炎可减轻患者炎症反应,改善PG及G-17水平,缓解患者临床症状,整体疗效确切。
Abstract:
Abstract:Objective To study the effects of Jianpi Xiaowei decoction combined with colloidal pectin bismuth capsules on the levels of gastrin-17 (G-17),pepsinogen (PG),and inflammatory factors in patients with chronic atrophic gastritis.Methods Eighty patients with chronic atrophic gastritis who came to our hospital for treatment from June 2019 to June 2022 were selected and randomly divided into a control group (40 cases,colloidal pectin bismuth capsules) and a treatment group (40 cases,colloidal pectin bismuth capsules+Jianpi Xiaowei decoction).Both groups were given basic treatment,and the therapeutic effect was evaluated.Serum inflammatory factors,PG,and GAS-17 levels were measured.Results The total effective rate of the treatment group was significantly higher than that of the control group (P<0.05);After treatment,the serum levels of interleukin-2(IL-2) and IL-6 in the treatment group were significantly lower than those in the control group (P<0.05);After treatment,the serum levels of PGI and G-17 in the treatment group were significantly higher than those in the control group,while the levels of PGII were significantly lower than those in the control group (P<0.05).Conclusion The combination of Jianpi Xiaowei decoction and colloidal pectin secret capsules can alleviate inflammation,improve PG and G-17 levels,alleviate clinical symptoms in patients with chronic atrophic gastritis,and have a definite overall therapeutic effect.

参考文献/References:

[1]Lerch JM,Pai RK,Brown I,et al.Subtyping intestinal metaplasia in patients with chronic atrophic gastritis:an interobserver variability study[J].Pathology,2022,54(3):262-268.
[2]Tong YL,Zhao X,Wang RL,et al.Therapeutic effect of berberine on chronic atrophic gastritis based on plasma and urine metabolisms[J].European Journal of Pharmacology,2021,908:174335.
[3]周永添,姚民武.滋培汤治疗胃阴不足型慢性萎缩性胃炎临床研究[J].广州中医药大学学报,2022,39(5):1027-1032.
[4]许金.健脾消萎汤治疗脾胃虚寒型慢性萎缩性胃炎的临床效果观察[J].甘肃科技,2020,36(21):148-150.
[5]中华医学会,中华医学会杂志社,中华医学会消化病学分会,等.慢性胃炎基层诊疗指南(实践版·2019)[J].中华全科医师杂志,2020,19(9):776-782.
[6]中华中医药学会脾胃病分会.慢性萎缩性胃炎中医诊疗共识意见[J].中医杂志,2010,51(8):749-753.
[7]中国中西医结合学会消化系统疾病专业委员会.慢性胃炎的中西医结合诊治方案[J].现代消化及介入诊疗,2005,10(3):181-184.
[8]孟莉,郭新春.半夏泻心汤联合二联疗法治疗顽固性Hp相关胃炎临床研究[J].陕西中医药大学学报,2019,42(1):123-125.
[9]林依娜.中药治疗慢性萎缩性胃炎临床疗效的Meta分析[J].陕西中医药大学学报,2018,41(4):52-58.
[10]陈朝聪,蔡水苗,刘海珊,等.胃炎宁颗粒联合胶体果胶铋治疗慢性萎缩性胃炎的临床研究[J].药物评价研究,2020,43(1):98-102.
[11]许永攀,王捷虹,雷根平.沈舒文教授治疗慢性萎缩性胃炎用药经验诠释[J].陕西中医药大学学报,2020,43(5):18-21.
[12]谢佳威,张萍,谷华伟.健脾消萎汤加减合香砂养胃丸辅助兰索拉唑三联疗法治疗脾胃虚寒型慢性萎缩性胃炎患者的疗效评价[J].黑龙江医药科学,2021,44(4):140-141.
[13]马艳春,胡建辉,吴文轩,等.黄芪化学成分及药理作用研究进展[J].中医药学报,2022,50(4):92-95.
[14]张柂儇,刘海龙,王瑞琼,等.黄芪化学成分和药理作用及Q-marker预测分析[J].中国新药杂志,2023,32(4):410-419.
[15]李力恒,陈昌瑾,胡晓阳,等.党参的化学成分及药理作用研究进展[J].中医药学报,2023,51(3):112-115.
[16]谢琦,程雪梅,胡芳弟,等.党参化学成分、药理作用及质量控制研究进展[J].上海中医药杂志,2020,54(8):94-104.
[17]张晓娟,左冬冬.白术化学成分及药理作用研究新进展[J].中医药信息,2018,35(6):101-106.
[18]杜航,何文生,胡红兰,等.白术活性成分药理作用研究进展[J].江苏中医药,2022,54(5):76-80.
[19]张慧,王艳艳,黄莉莉,等.基于网络药理学探讨吴茱萸-黄连药对治疗胃炎的机制研究[J].中医药学报,2020,48(8):29-36.
[20]梁靖蓉,麦凤怡,李陈广,等.吴茱萸碱的药理学研究进展[J].中国药理学通报,2022,38(10):1457-1461.
[21]陶梅,张沥,张玲霞,等.实验性萎缩性胃炎大鼠细胞因子IL-6,IL-8的变化及意义[J].山西医科大学学报,2010,41(8):673-676.
[22]袁媛,王荟,许智华.乳铁蛋白胶囊联合铋剂四联疗法治疗小儿幽门螺杆菌相关性胃炎的疗效[J].福建医科大学学报,2023,57(2):117-121.
[23]陈俊玲,禹霞,戴明.芍药八味汤结合穴位埋线对慢性萎缩性胃炎患者疗效、胃功能及血清炎症因子水平的影响[J].辽宁中医杂志,2022,49(1):142-145.
[24]安晓霞,王振刚,苏传丽,等.基于络病理论的清胃通络方对于慢性糜烂性胃炎(CEG)伴癌前期病变(PLGC)临床疗效的研究[J].现代中医药,2021,41(5):67-71.
[25]谢东明,黄治胜,罗巧.丹芪祛瘀止痛汤对慢性萎缩性胃炎患者血清胃蛋白酶原及相关指标的影响[J].陕西中医,2022,43(4):487-491.
[26]罗长琴,肖翔,申光富.慢性萎缩性胃炎伴Hp感染患者血清GH、PGⅠ/PGⅡ、TGF-βRⅡ、IL-6和TNF-α水平的变化及临床意义[J].海南医学,2021,32(18):2334-2337.
[27]朱春花,吕国强.益气化瘀解毒法对老年Hp相关慢性萎缩性胃炎患者血清PGⅠ/PGⅡ、HIF-1α、VEGF水平的影响[J].中国老年学杂志,2022,42(3):573-577.
[28]袁惠,王溪.不同OLGIM分期胃炎患者PGⅠ、PGR水平变化及HP感染状况分析[J].海南医学,2023,34(1):26-29.
[29]周明霞,徐惠明.疏肝理气方治疗疣状胃炎临床疗效及对血清pgⅠ、pgⅡ及CRP表达水平的影响[J].湖北中医药大学学报,2020,22(6):32-35.
[30]周昕瞳.柴胡疏肝汤加减治疗慢性萎缩性胃炎肝胃不和证患者的疗效及其对血清胃泌素G17水平的影响[J].中国民康医学,2018,30(17):66-67.

相似文献/References:

[1]殷苗苗睢建亮王梦蕾刘会云刘齐超一峰王珍.摩罗丹浓缩丸治疗慢性萎缩性胃炎的药效及作用机制[J].现代中医药,2024,(02):098.[doi:10.13424/j.cnki.mtcm.2024.02.018]
 YIN MiaomiaoSUI JianliangWANG MengleiLIU HuiyunLIU QichaoWU YifengWANG Zhen.Morodan Concentrated Pills for the Treatment of Chronic Atrophic Gastritis and Its Mechanism of Action[J].Modern Traditional Chinese Medicine,2024,(01):098.[doi:10.13424/j.cnki.mtcm.2024.02.018]

备注/Memo

备注/Memo:
基金项目:陕西省中医药管理局基金项目(SZY-NLTL-2022-029)
更新日期/Last Update: 2024-01-27